These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 22817609)
1. Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. Yap DY; Ma MK; Tang CS; Chan TM Nephrology (Carlton); 2012 Nov; 17(8):676-80. PubMed ID: 22817609 [TBL] [Abstract][Full Text] [Related]
2. Long-term data on tacrolimus treatment in lupus nephritis. Yap DY; Ma MK; Mok MM; Kwan LP; Chan GC; Chan TM Rheumatology (Oxford); 2014 Dec; 53(12):2232-7. PubMed ID: 24996908 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Mak SK; Lo KY; Lo MW; Chan SF; Tong GM; Wong PN; Wong AK Nephrology (Carlton); 2008 Jun; 13(4):331-6. PubMed ID: 18476916 [TBL] [Abstract][Full Text] [Related]
4. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years. Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551 [TBL] [Abstract][Full Text] [Related]
5. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192 [TBL] [Abstract][Full Text] [Related]
6. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263 [TBL] [Abstract][Full Text] [Related]
7. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH; Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070 [TBL] [Abstract][Full Text] [Related]
8. Effects of concomitant hepatitis C virus infection in patients with underlying lupus nephritis on long-term renal outcome. Mitwalli AH; Hayat A; Alwakeel J; Hammad D Nephrol Dial Transplant; 2012 Feb; 27(2):627-32. PubMed ID: 21771749 [TBL] [Abstract][Full Text] [Related]
9. Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. Yap DYH; Tang C; Chan GCW; Kwan LPY; Ma MKM; Mok MMY; Chan TM J Rheumatol; 2018 Dec; 45(12):1663-1670. PubMed ID: 30275264 [TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548 [TBL] [Abstract][Full Text] [Related]
11. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ]. Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309 [TBL] [Abstract][Full Text] [Related]
12. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874 [TBL] [Abstract][Full Text] [Related]
14. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children. Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528 [TBL] [Abstract][Full Text] [Related]
16. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338 [TBL] [Abstract][Full Text] [Related]
17. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458 [TBL] [Abstract][Full Text] [Related]
18. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Tse KC; Lam MF; Tang SC; Tang CS; Chan TM Lupus; 2007; 16(1):46-51. PubMed ID: 17283585 [TBL] [Abstract][Full Text] [Related]
19. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases. Shen K; Yu Y; Tang Z; Liu Z; Li L Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205 [TBL] [Abstract][Full Text] [Related]
20. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]